Treatment with AZA1 at 5 and 10 μM resulted in significantly reduced lamellipodia (p<0.01) and filopodia (p<0.01) formation in 22Rv1 prostate cancer cells after 24 h compared to EGF-stimulated cells (Figure 4B). The gene discussed is EGF; the disease is prostate carcinoma.